The claim requires verification of three core elements: (1) which cystic fibrosis treatment is referenced, (2) the actual timeline between TGA approval and PBS listing, and (3) whether this represents unusual government delay.
The claim most likely refers to **Kalydeco (ivacaftor)**, the first approved treatment for cystic fibrosis patients with the G551D CFTR gene mutation [1].
**Historical Delay Data:**
- Studies documenting average 34.2-month delays from TGA approval to PBS listing during 2000-2009 period cover both Labor and Coalition governments [6]
- Average delays of 13.6+ months existed during Labor government periods [6]
- ANAO's audit of PBS governance issues identifies systemic problems spanning multiple government terms [7]
**Specific CF Treatment Precedent:**
- No documented instance of Labor government specifically expediting CF treatment PBS listings faster than the Coalition [6][7]
- The systemic delays in the PBS process predate the Coalition's 2013-2022 term [6]
**Conclusion:** PBS listing delays appear to be **endemic to the Australian regulatory system**, not unique to either party.
# # # # # # 調査 nounChousa 結果 nounKekka
Both governments have presided over similar delays.
The claim is misleading for two reasons:
**First, the timeline is factually inaccurate.** For Kalydeco (the likely subject), the actual wait from TGA approval to PBS listing was **17 months, not 4 months** [1][4].
Neither matches the "4 months" stated.
**Second, the claim implies improper government delay without evidence.** Even if a 4-month delay had occurred, this would be **consistent with normal PBS approval timelines** (averaging 6.6+ months), not evidence of extraordinary obstruction [6][7].
The delays are attributable to PBAC assessments and government-industry price negotiations—standard regulatory processes [2][3][6].
**Third, the claim lacks necessary context about systemic delays.** PBS listing delays are a **documented structural issue affecting all governments**, not unique to the Coalition.
The Conversation is a credible publication with academic rigor, but it has a documented left-leaning bias that may lead to emphasizing Coalition criticism while underreporting equivalent delays under Labor [8][9].
The claim is misleading for two reasons:
**First, the timeline is factually inaccurate.** For Kalydeco (the likely subject), the actual wait from TGA approval to PBS listing was **17 months, not 4 months** [1][4].
Neither matches the "4 months" stated.
**Second, the claim implies improper government delay without evidence.** Even if a 4-month delay had occurred, this would be **consistent with normal PBS approval timelines** (averaging 6.6+ months), not evidence of extraordinary obstruction [6][7].
The delays are attributable to PBAC assessments and government-industry price negotiations—standard regulatory processes [2][3][6].
**Third, the claim lacks necessary context about systemic delays.** PBS listing delays are a **documented structural issue affecting all governments**, not unique to the Coalition.
The Conversation is a credible publication with academic rigor, but it has a documented left-leaning bias that may lead to emphasizing Coalition criticism while underreporting equivalent delays under Labor [8][9].